Trial Profile
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone (Primary) ; Prednisone (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Incyte Corporation
- 12 Mar 2020 Status changed from recruiting to discontinued due to insufficient efficacy in a separate phase III study.
- 14 Feb 2020 This trial is Discontinued in UK, according to European Clinical Trials Database record.
- 27 Jan 2020 This trial has been discontinued in France, according to European Clinical Trials Database.